280 related articles for article (PubMed ID: 22468861)
1. Premixed insulin aspart 30 (BIAsp 30) versus premixed human insulin 30 (BHI 30) in gestational diabetes mellitus: a randomized open-label controlled study.
Balaji V; Balaji MS; Alexander C; Srinivasan A; Suganthi SR; Thiyagarajah A; Seshiah V
Gynecol Endocrinol; 2012 Jul; 28(7):529-32. PubMed ID: 22468861
[TBL] [Abstract][Full Text] [Related]
2. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
Mäkelä JK; Schmüser C; Askonen K; Saukkonen T
Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
[TBL] [Abstract][Full Text] [Related]
3. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
Chen SF; Li H
Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
[TBL] [Abstract][Full Text] [Related]
4. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
Niromanesh S; Alavi A; Sharbaf FR; Amjadi N; Moosavi S; Akbari S
Diabetes Res Clin Pract; 2012 Dec; 98(3):422-9. PubMed ID: 23068960
[TBL] [Abstract][Full Text] [Related]
5. Premixed insulin aspart 30 (Biasp 30) vs. premixed human insulin 30 (BHI 30) in gestational diabetes mellitus--a pilot study.
Balaji V; Balaji MS; Alexander C; Ashalata S; Sheela Suganthi R; Suresh S; Seshiah V
J Assoc Physicians India; 2010 Feb; 58():99-101. PubMed ID: 20653150
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
[TBL] [Abstract][Full Text] [Related]
7. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
9. Multicenter, open-label, non-randomized, non-interventional observational study of safety of treatment initiation with a biphasic insulin aspart.
Wolnik B; Hak L
Expert Opin Drug Saf; 2013 Mar; 12(2):137-44. PubMed ID: 23289795
[TBL] [Abstract][Full Text] [Related]
10. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
[TBL] [Abstract][Full Text] [Related]
11. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
12. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
[TBL] [Abstract][Full Text] [Related]
13. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
14. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
[TBL] [Abstract][Full Text] [Related]
15. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
[TBL] [Abstract][Full Text] [Related]
16. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U; Ashwell SG; Home PD
Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
[TBL] [Abstract][Full Text] [Related]
17. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
19. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
